GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۱۰ — حداکثر ۱۵۰ • واحد: percent
حداقل ۵ — حداکثر ۱۵۰ • واحد: percent
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- GAP Stage I0–3
- GAP Stage II4–5
- GAP Stage III6–8
The GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality calculates stratifying pneumonia severity, respiratory failure progression, and inpatient admission requirements. Key inputs include gender. Scores guide determining appropriate admission level (floor versus ICU), tailoring antimicrobial therapy, and ventilatory support. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Provides 1, 2, and 3-year mortality estimates for IPF patients. The GAP Index uses Gender, Age, and Physiology (FVC and DLCO) to predict mortality risk and guide clinical management decisions.
Clinical Indication
The GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality is indicated for bedside clinical practice to support Provides 1, 2, and 3-year mortality estimates for IPF patients. The GAP Index uses Gender, Age, and Physiology (FVC and DLCO) to predict mortality risk and guide clinical management decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with community-acquired pneumonia, COPD exacerbations, acute asthma, pulmonary embolism, or acute respiratory distress. Clinical application is indicated across Respiratory care units, emergency pulmonary triage, sleep clinics, and medical floors.
Limitations & Contraindications
Peripheral pulse oximetry loses reliability in hypoperfusion, severe vasoconstriction, methemoglobinemia, or carboxyhemoglobinemia.
Clinical Pearls & Action Plan
Synchronous evaluation of arterial blood gas (PaO2/FiO2), mechanics of breathing, and clinical trajectory guides respiratory failure management.
GAP Score = Gender points + Age points + FVC points + DLCO points (0-8 total)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| gender | string | Yes | Patient's gender (males have higher mortality risk in IPF) |
| age | integer | Yes | Patient's age in years(years) |
| fvc_percent_predicted | float | Yes | Forced Vital Capacity (FVC) as percentage of predicted normal value(percent) |
| dlco_percent_predicted | float | No | Diffusing capacity for carbon monoxide (DLCO) as percentage of predicted normal value. Use null if cannot perform test(percent) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–3 | GAP Stage I | Low mortality risk |
| 4–5 | GAP Stage II | Intermediate mortality risk |
| 6–8 | GAP Stage III | High mortality risk |
Evidence-Based References (EBM)
- Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.DOI: 10.7326/0003-4819-156-10-201205150-00004
- Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723-8. doi: 10.1378/chest.13-1474.DOI: 10.1378/chest.13-1474
- Paterniti MO, Bi Y, Rekić D, et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.DOI: 10.1513/AnnalsATS.201606-458OC